Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study to Assess the Effect of Naltrexone Hydrochloride and Bupropion Hydrochloride Extended Release Combination on the Occurrence of Major Adverse Cardiovascular Events in Overweight and Obese Subjects With Cardiovascular Disease
NCT02638129 is registered in ClinicalTrials.gov with Orexigen Therapeutics, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study to Assess the Effect of Naltrexone Hydrochloride and Bupropion Hydrochloride Extended Release Combination on the Occurrence of Major Adverse Cardiovascular Events in Overweight and Obese Subjects With Cardiovascular Disease
- Lead sponsor
- Orexigen Therapeutics, Inc
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- January 31, 2016
- Completion date
- June 30, 2016
- Enrollment
- 67 (actual)
- Sites
- 139
Conditions
As the registry lists them; a condition with its own page is linked.